Azepine Benzodiazepine Composition for High GABAA Affinity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing benzodiazepine drugs have limitations in terms of efficacy and side effects, necessitating the development of new compounds with improved pharmacokinetic properties and reduced toxicity.
Innovation Solution
Development of a class of benzodiazepine compounds with specific structural modifications, including various substituents and fused ring systems, to enhance their binding affinity to GABAA receptors, thereby improving therapeutic effects and reducing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing benzodiazepine drugs are used, then anti-anxiety, sedative and hypnotic effects are achieved, but toxicity and side effects increase
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of benzodiazepine compounds through systematic variation of substituents at specific positions (R1-R10, Y, Q, R3, L, n1, n2, X, M). These structural parameter changes optimize the binding affinity to GABAA receptors while reducing toxicity, achieving improved therapeutic index through precise chemical modification rather than fundamental mechanism changes
Solution Approach 2:
The patent implements local quality by introducing specific functional groups and substituents at particular positions in the benzodiazepine molecule (e.g., Y at position 2, Q at position 1, various R groups at positions 3-10). Each local modification targets specific interaction sites with the GABAA receptor, optimizing binding at critical locations while maintaining overall molecular framework, thereby enhancing efficacy locally without proportionally increasing systemic toxicity
2Reliability
If benzodiazepine drugs bind to GABAA receptors, then synaptic inhibitory effect is strengthened, but binding affinity limitations reduce efficacy
Solution Approach 1:
The patent employs composite materials principle by creating complex substituted benzodiazepine molecules that combine multiple functional elements: the core diazepine structure provides basic binding, while attached substituents (aromatic rings, heterocycles, halogens, alkyl groups) provide additional binding interactions. This composite molecular design enables simultaneous engagement with multiple receptor sites or increased affinity at primary sites, achieving high binding affinity without sacrificing the fundamental synaptic inhibitory mechanism
Solution Approach 2:
The patent applies segmentation by dividing the binding interaction into distinct components: the parent benzodiazepine structure provides core binding functionality, while separate substituent groups (R1-R10, Y, Q, R3, L, n1, n2, X, M) provide additional binding contributions. This modular segmentation allows independent optimization of each component's contribution to overall binding affinity, enabling precise control over the strength and specificity of GABAA receptor interaction
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified benzodiazepine compounds demonstrate enhanced efficacy and reduced toxicity, providing improved anti-anxiety, sedative, and hypnotic effects with fewer adverse reactions.
Implementation Method 1
There are specific binding sites with high affinity for diazepam in the brain, known as benzodiazepine receivers... Benzodiazepine drugs can enhance the GABAergic neurotransmission function and synaptic inhibitory effect, and strengthen the binding of GABA to GABAA receivers
Data Source
AI summary
A compound as represented by general formula I, and a composition and the use thereof, wherein the compound as represented by general formula I has the following structure; and a pharmaceutically acceptable salt, a stereoisomer, a prodrug, a solvate and a deuterated compound thereof.